Cardiotoxicity of novel molecular targeted therapies of cancer

[1]  R. Figlin,et al.  Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib , 2011, Journal of the National Cancer Institute.

[2]  C. Porta,et al.  Toxicities of targeted therapy and their management in kidney cancer. , 2011, European urology.

[3]  R. Witteles,et al.  Trastuzumab-related cardiac dysfunction. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  R. Kurzrock,et al.  Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? , 2010, The oncologist.

[5]  R. Autorino,et al.  Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  U. Dafni,et al.  Assessment of trastuzumab-related cardiac dysfunction in the Herceptin Adjuvant (HERA) Trial with 3.6 years median follow- up. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Bhargava.  VEGF kinase inhibitors: how do they cause hypertension? , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[9]  M. Piccart-Gebhart,et al.  Cardiac toxicity with anti-HER-2 therapies-what have we learned so far? , 2009, Targeted Oncology.

[10]  J. Soria,et al.  Review Management of Hypertension in Angiogenesis Inhibitor-treated Patients , 2022 .

[11]  A. Jarkowski,et al.  Response to Sorafenib After Sunitinib‐Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature , 2009, Pharmacotherapy.

[12]  A. Ardavanis,et al.  Cardiotoxicity induced by tyrosine kinase inhibitors , 2009, Acta oncologica.

[13]  J. Bergh.  Quo vadis with targeted drugs in the 21st century? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Zielinski,et al.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[16]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[17]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.